Ethinyl estradiol and levonorgestrel patch phase 3 data clarification
- PMID: 33744301
- DOI: 10.1016/j.contraception.2020.12.017
Ethinyl estradiol and levonorgestrel patch phase 3 data clarification
Conflict of interest statement
Declaration of competing interest Dr. Creinin serves on an Advisory Board for Evofem, Mayne, Merck & Co., Searchlight and TherapeuticsMD and is a consultant for Danco, Estetra, Mayne, Medicines360, and Merck & Co. His department receives research funding for contraceptive research from Daré, HRA Pharma, Medicines360, Merck & Co. and Sebela.
Comment in
-
Author response to ethinyl estradiol and levonorgestrel Phase 3 data clarification.Contraception. 2021 Aug;104(2):217. doi: 10.1016/j.contraception.2021.03.012. Epub 2021 Mar 16. Contraception. 2021. PMID: 33741355 No abstract available.
Comment on
-
Efficacy, safety, and tolerability of a levonorgestrel/ethinyl estradiol transdermal delivery system: Phase 3 clinical trial results.Contraception. 2021 Mar;103(3):137-143. doi: 10.1016/j.contraception.2020.11.011. Epub 2020 Nov 28. Contraception. 2021. PMID: 33259782 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources